How a test we developed is helping NHS clinicians prevent severe progression of COVID in patients.
Ronapreve is a combination of two monoclonal antibodies (casirivimab and imdevimab). Clinical trials have shown good effectiveness in preventing progression to severe COVID disease, including a potential reduction in mortality of approximately 20%.
Ronapreve was rolled out in the NHS in late September 2021. There are strict criteria for usage. One of these is COVID-19 serology. To be specific, the policy requires measurement of patients’ SARS-CoV 2 anti-S antibodies. Testing for this has been available at the Halo laboratory since January 2021.
Since Ronapreve went live in the NHS, we have been supporting NHS clinicians to determine if their patients are eligible for this treatment with fast (within 24 hours) COVID anti-S serology. This test is available 24/7 every day of the year.
Generally, Ronapreve is not given without this important COVID serology result. By providing a rapid TAT, we are helping NHS doctors treat COVID-19 patients and improving patient care.